Cyclosporine absorption profiles in pediatric kidney and liver transplant patients
dc.contributor.author | Ettenger, Robert | en_US |
dc.contributor.author | Soergel, Marianne | en_US |
dc.contributor.author | Hoyer, Peter F. | en_US |
dc.contributor.author | Kovarik, John M. | en_US |
dc.contributor.author | Punch, Jeffrey D. | en_US |
dc.date.accessioned | 2006-09-11T19:25:53Z | |
dc.date.available | 2006-09-11T19:25:53Z | |
dc.date.issued | 2003-12 | en_US |
dc.identifier.citation | Kovarik, J. M.; Hoyer, Peter F.; Ettenger, Robert; Punch, Jeffrey; Soergel, Marianne; (2003). "Cyclosporine absorption profiles in pediatric kidney and liver transplant patients." Pediatric Nephrology 18(12): 1275-1279. <http://hdl.handle.net/2027.42/47821> | en_US |
dc.identifier.issn | 1432-198X | en_US |
dc.identifier.issn | 0931-041X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/47821 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14577021&dopt=citation | en_US |
dc.description.abstract | Cyclosporine absorption profiling uses either the area under the concentration curve in the first 4 h post dose, AUC(0–4), or the concentration 2 h post dose (C2) to optimize immunosuppression in adult kidney and liver transplantation. We characterized C2 versus AUC(0–4) relationships over time after transplant and across transplant indications in 56 pediatric transplant patients. There were 36 kidney transplant patients aged 9.7±3.9 years. Nineteen of these patients were studied in the de novo period on day 7 post transplant and 17 in the maintenance phase more than 1 year post transplant. In addition, 20 liver transplant patients aged 8.9±4.2 years were studied in the maintenance phase. All patients had five blood samples collected over the 12-h dose interval that were analyzed by validated assay methods at a central laboratory. Pediatric C2 values were 1,463±658 ng/ml for de novo kidney, 954±322 ng/ml for maintenance kidney, and 619±339 ng/ml for maintenance liver transplant patients. C2 was a strong predictor of AUC(0–4) in all three pediatric groups, with coefficients of determination ( r 2 ) ranging from 0.861 to 0.936. Although data were limited from the de novo period, the C2 versus AUC(0–4) regression was consistent over time after transplant and between transplant indications, with a regression slope of 2.50 in de novo kidney, 2.54 in maintenance kidney, and 2.76 in maintenance liver transplant recipients. These slopes were also comparable to that in adult maintenance kidney transplant patients (2.60). In conclusion, C2 versus AUC(0–4) relationships demonstrated consistency over time (de novo vs. maintenance phase), between transplant indications (kidney vs. liver), and across age groups (pediatric vs. adult patients). Average C2 values achieved with current pediatric cyclosporine dosing practices cluster around the target C2 ranges recommended for adults. | en_US |
dc.format.extent | 149321 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; IPNA | en_US |
dc.subject.other | Medicine | en_US |
dc.subject.other | Kidney Transplantation | en_US |
dc.subject.other | Therapeutic Drug Monitoring | en_US |
dc.subject.other | Cyclosporine | en_US |
dc.subject.other | Liver Transplantation | en_US |
dc.subject.other | Immunosuppression | en_US |
dc.title | Cyclosporine absorption profiles in pediatric kidney and liver transplant patients | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor, MI 48109–0331, USA | en_US |
dc.contributor.affiliationother | Novartis Pharma AG, Building WSJ 27.4093, 4002 Basel, Switzerland | en_US |
dc.contributor.affiliationother | Division of Pediatric Nephrology, Mattel Children’s Hospital at UCLA, Los Angeles, CA 90095–1752, USA | en_US |
dc.contributor.affiliationother | Novartis Pharma AG, Building WSJ 27.4093, 4002 Basel, Switzerland | en_US |
dc.contributor.affiliationother | Department of Pediatric Nephrology, Universitätsklinik Essen, 45122 Essen, Germany | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 14577021 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/47821/1/467_2003_Article_1260.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s00467-003-1260-8 | en_US |
dc.identifier.source | Pediatric Nephrology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.